GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (STU:UP0) » Definitions » Institutional Ownership

Ultragenyx Pharmaceutical (STU:UP0) Institutional Ownership : 57.89% (As of Jun. 06, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Ultragenyx Pharmaceutical Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ultragenyx Pharmaceutical's institutional ownership is 57.89%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ultragenyx Pharmaceutical's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ultragenyx Pharmaceutical's Float Percentage Of Total Shares Outstanding is 85.76%.


Ultragenyx Pharmaceutical Institutional Ownership Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Institutional Ownership Chart

Ultragenyx Pharmaceutical Historical Data

The historical data trend for Ultragenyx Pharmaceutical can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 67.16 65.61 56.64 56.72 60.53 59.89 59.80 57.71 57.84 57.89

Ultragenyx Pharmaceutical Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Ultragenyx Pharmaceutical (STU:UP0) Business Description

Traded in Other Exchanges
Address
60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical (STU:UP0) Headlines

No Headlines